Yabao has been ranked in the top 100 of China's pharmaceutical industry for 7 consecutive years.

The list of China's top 100 pharmaceutical industry enterprises is based on the "China Pharmaceutical Statistics Annual Report", the only official data reflecting the economic health of the country's pharmaceutical industry, and is measured by four quantitative comprehensive indicators of main business income, profit, total assets and liabilities, and consists of the top 100 companies.
has been on the list for seven years in a row.
"China's pharmaceutical research and development product line of the best industrial enterprises" list, is China's pharmaceutical industry information center in order to track the real-time development of domestic and foreign research and development dynamics, excavate the domestic pharmaceutical research and development field of the strongest voice, jointly launched by the China Pharmaceutical Industry Research Institute, Shanghai Pharmaceutical Industry Research Institute.
results have received a lot of attention and recognition from the industry and enterprises.
Abao has been on the list for many years, thanks to the company's continuous research and development investment and perfect research and development layout.
understood that Abao Pharmaceuticals has always been scientific and technological innovation as an engine of enterprise development, and constantly increase the introduction of scientific research personnel and the absorption of advanced technology.
, Abao's research and development is divided into innovative drugs, generic drugs, Chinese medicine and large health products four major sectors.
five of the innovative drug sectors have been approved for clinical use, of which SY-004 (Agratin hydrochloride) has entered phase II clinical stage, and the remaining four innovative drugs are in phase I clinical stage.
In order to promote research and development innovation, Yabao Pharmaceuticals not only has its own research institutes in the United States, Suzhou, Beijing and Shanxi, has a nationally recognized enterprise technology center, a national postdoctoral research workstation, academician workstation, a national engineering research center for pharmaceutical preparations, but also with Lilly Pharmaceuticals, the United Kingdom National Medical College, the University of South Australia Joint Laboratory and other well-known pharmaceutical companies, research and development institutions to maintain long-term cooperation, through joint development and technology to continuously improve the innovation capacity and scientific research level.
" innovation is the core competitiveness of enterprises, innovative drugs are the future of enterprises.
, chairman of Yabao Pharmaceuticals, stressed the importance of innovation. on the next step in development, Ren Wuxian said:
The company will continue to increase research and development of innovative drugs, in cooperation with the Institute of Microbiology of the Chinese Academy of Sciences, into biopharmaceutical research and development, from traditional pharmaceutical to biopharmaceutical transformation and development."
"